Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical ...

Insights derived from one of the largest datasets with over 250 million harmonized variant calls from over 8,000 tumor-normal ...

The settlement will provide funding to state and local governments nationwide to support recovery efforts related to the ...

Posters highlight antigen-independent delivery, differentiated efficacy and broad payload versatility of ultra pH-sensitive ...

(PRs) among 38 response-evaluable non-small cell lung cancer (NSCLC) patients (ORR 26%), including three of seven squamous cell NSCLC patients (ORR 43%)Five confirmed PRs among 19 response-evaluable ...

The U.S. FDA has granted Fast Track designation for mRNA-4359 in combination with pembrolizumab for the treatment of checkpoint inhibitor refractory unresectable or metastatic melanoma with PD-L1+ ...

Cantargia AB (Publ) (Nasdaq Stockholm:CANTA) today reported that the rationale and study design of the phase 1b/2 clinical trial investigating nadunolimab in combination with immune-checkpoint ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology ...

Please replace the release with the following corrected version due to multiple revisions.The updated release reads:MOUNTAIN VALLEY MD ANNOUNCES APPOINTMENT OF ADVISORS AND STOCK OPTION GRANTSMountain ...

Data demonstrate a scalable approach to better understand tumor cell behavior and inform drug developmentDALLAS--(BUSINESS WIRE)--SingleCell Biotechnology, a biotechnology company developing ...

The trial compared hospital stay duration of severely burned patients treated with intact fish-skin grafts and patients ...

Encouraging early results catalyze continued investigation in the MATISSE Phase 2 study evaluating IPH5201, a first-in-class ...